Polar Asset Management Partners Inc. Purchases Shares of 272,571 Adaptive Biotechnologies Corporation $ADPT

Polar Asset Management Partners Inc. purchased a new position in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 272,571 shares of the company’s stock, valued at approximately $5,847,000. Polar Asset Management Partners Inc. owned about 0.17% of Adaptive Biotechnologies as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd bought a new position in Adaptive Biotechnologies during the 4th quarter valued at approximately $28,000. Allworth Financial LP bought a new stake in shares of Adaptive Biotechnologies in the 2nd quarter worth approximately $35,000. EverSource Wealth Advisors LLC grew its position in shares of Adaptive Biotechnologies by 197.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after buying an additional 1,565 shares during the last quarter. KBC Group NV purchased a new position in shares of Adaptive Biotechnologies during the first quarter valued at approximately $45,000. Finally, T. Rowe Price Investment Management Inc. bought a new position in shares of Adaptive Biotechnologies during the fourth quarter valued at approximately $51,000. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Insider Buying and Selling at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, CEO Chad M. Robins sold 278,676 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $24.48, for a total transaction of $6,821,988.48. Following the completion of the transaction, the chief executive officer owned 2,180,518 shares of the company’s stock, valued at approximately $53,379,080.64. This trade represents a 11.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Harlan S. Robins sold 492,400 shares of Adaptive Biotechnologies stock in a transaction that occurred on Tuesday, July 21st. The shares were sold at an average price of $21.89, for a total transaction of $10,778,636.00. Following the transaction, the insider owned 812,058 shares of the company’s stock, valued at $17,775,949.62. The trade was a 37.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 2,062,325 shares of company stock valued at $46,659,069 over the last three months. 5.70% of the stock is currently owned by corporate insiders.

Adaptive Biotechnologies Stock Performance

Shares of Adaptive Biotechnologies stock opened at $26.25 on Wednesday. Adaptive Biotechnologies Corporation has a 12 month low of $12.00 and a 12 month high of $26.49. The firm has a market capitalization of $4.19 billion, a P/E ratio of -64.02 and a beta of 2.08. The company has a current ratio of 4.79, a quick ratio of 4.68 and a debt-to-equity ratio of 2.22. The business has a fifty day simple moving average of $22.40 and a two-hundred day simple moving average of $17.45.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). The business had revenue of $71.55 million during the quarter, compared to analysts’ expectations of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The firm’s quarterly revenue was up 21.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.17) earnings per share. On average, equities analysts forecast that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ADPT. TD Cowen raised their price target on Adaptive Biotechnologies from $25.00 to $28.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. JPMorgan Chase & Co. decreased their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. BTIG Research lifted their target price on shares of Adaptive Biotechnologies from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Finally, Morgan Stanley boosted their price target on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.42.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.